Since June, 85,600 boxes of anti-obesity medications have been sold in France. These medications, including Mounjaro and Wegovy, are now partially reimbursed by the French Health Insurance, making them more accessible to those affected by obesity. Nearly 18% of French adults are affected by obesity, a condition described by the National Collective of Obesity Associations (CNAO) as "a disease of adipose tissue that fibroses." The CNAO, a group representing individuals and organizations focused on obesity, has long criticized the persistent stigma and misconceptions surrounding the condition. In the Provence-Alpes-Côte d'Azur region, more than 10,500 boxes of these medications have been dispensed in pharmacies, according to the regional council of the pharmacists' order, confirming a report by RTL, a French news outlet. Anne-Sophie Joly, president of the CNAO, expressed hope that the partial reimbursement of these medications represents "finally a chance for therapeutic equality with other diseases." She noted that since the World Health Organization (WHO) classified obesity as a chronic disease in 1997, people with obesity have faced unequal treatment in healthcare. "We treat the pathologies associated with obesity, which are 18, with the coronavirus being the 19th pathology, but we have never treated the cause of obesity," she said during a broadcast on ICI Provence. Joly emphasized that obesity is not simply a matter of eating less and moving more, but a complex condition involving biological and environmental factors. While the French Health Insurance now partially covers the cost of Mounjaro and Wegovy, only about 1.3 million people in France are eligible for this care, and the number of those accessing it remains low. Joly criticized the lack of training among health professionals, stating that there is a "lack of knowledge of the disease itself" and a need to educate both medical and paramedical staff. She also pointed out the ongoing issue of "fat phobia," where some healthcare providers may refuse to treat individuals with obesity due to stigma. "We do not need discrimination by saying, 'I do not want to treat a person in a situation of obesity,'" she said, emphasizing that obesity is a disease, not a personal failing. To address the root causes of the obesity epidemic, Joly called on the French government and the European Union to regulate the practices of food companies. She noted that "70 years ago, there was not as much obesity in the world" and urged a reevaluation of why obesity rates have risen so sharply. According to the French Observatory of Obesity Epidemiology (OFÉO), about 18% of adults in France are affected by obesity, highlighting the scale of the issue and the need for comprehensive public health strategies.